Daisuke Taniguchi

Daisuke Taniguchi

Auto-generated profile, based on publicly available information

Daisuke Taniguchi

Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YTYosuke Takeoka
Yosuke Takeoka
KMKeitaro Matsumoto
Keitaro Matsumoto
DTDaisuke Taniguchi
Daisuke Taniguchi
TTTomoshi Tsuchiya
Tomoshi Tsuchiya
RMRyusuke Machino
Ryusuke Machino
TNTakeshi Nagayasu
Takeshi Nagayasu
Various strategies have been attempted to replace esophageal defects with natural or artificial substitutes using tissue engineering. However, these methods have not yet reached clinical application because of the high risks related to their immunogenicity or insufficient biocompatibility. In this study, we developed a scaffold-free structure with a mixture of cell types using bio-three-dimensional (3D) printing technology and assessed its characteristics in vitro and in vivo after transplantation into rats. Normal human dermal fibroblasts, human esophageal smooth muscle cells, human bone marrow-derived mesenchymal stem cells, and human umbilical vein endothelial cells were purchased and used as a cell source. After the preparation of multicellular spheroids, esophageal-like tube structures were prepared by bio-3D printing. The structures were matured in a bioreactor and transplanted into 10-12-week-old F344 male rats as esophageal grafts under general anesthesia. Mechanical and histochemical assessment of the structures were performed. Among 4 types of structures evaluated, those with the larger proportion of mesenchymal stem cells tended to show greater strength and expansion on mechanical testing and highly expressed α-smooth muscle actin and vascular endothelial growth factor on immunohistochemistry. Therefore, the structure with the larger proportion of mesenchymal stem cells was selected for transplantation. The scaffold-free structures had sufficient strength for transplantation between the esophagus and stomach using silicon stents. The structures were maintained in vivo for 30 days after transplantation. Smooth muscle cells were maintained, and flat epithelium extended and covered the inner surface of the lumen. Food had also passed through the structure. These results suggested that the esophagus-like scaffold-free tubular structures created using bio-3D printing could hold promise as a substitute for the repair of esophageal defects.

1 February 2018 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
NMNaoto Matsuo
Naoto Matsuo
KMKeitaro Matsumoto
Keitaro Matsumoto
YTYasuaki Taura
Yasuaki Taura
YSYuka Sakakibara
Yuka Sakakibara
DTDaisuke Taniguchi
Daisuke Taniguchi
TNTakeshi Nagayasu
Takeshi Nagayasu
The incidence of pectus excavatum has been estimated to be between 0.1% and 0.8% though a large autopsy series reports. After publication of the Nuss procedure for pectus excavatum, it became widely accepted. However, there are still some complications, such as over-correction and recurrence. To reduce differences in the procedure due to surgeons’ experience level, preoperative simulation may be useful. Thus, we performed simulated surgery using a specific patient’s three-dimensional (3D) chest wall model made by a 3D printer before operation. A 13-year-old male patient with a severe deformity of the chest underwent the Nuss procedure. As in the simulation, bars were inserted into the 5th and 7th intercostal spaces (ICS), leading to improvement of the chest wall. This simulation can increase surgeons’ confidence to improve the deformity by determination of the number and insertion sites of bars.

15 July 2019 in Respiratory Research
Verified
Journal Article
Open access
PDF file
TMTakuto Miyamura
Takuto Miyamura
NSNoriho Sakamoto
Noriho Sakamoto
TKTomoyuki Kakugawa
Tomoyuki Kakugawa
DODaisuke Okuno
Daisuke Okuno
HYHirokazu Yura
Hirokazu Yura
HMHiroshi Mukae
Hiroshi Mukae
Acute exacerbation of interstitial pneumonia (AE-IP) is a serious complication of pulmonary surgery in patients with IP. However, little is known about AE-IP after non-pulmonary surgery. The aim of this study was to determine the frequency of AE-IP after non-pulmonary surgery and identify its risk factors. One hundred and fifty-one patients with IP who underwent pulmonary surgery and 291 who underwent non-pulmonary surgery were retrospectively investigated. AE-IP developed in 5 (3.3%) of the 151 patients in the pulmonary surgery group and 4 (1.4%) of the 291 in the non-pulmonary surgery group; the difference was not statistically significant. A logistic regression model showed that serum C-reactive protein (CRP) was a predictor of AE-IP in the non-pulmonary surgery group (odds ratio 1.187, 95% confidence interval 1.073–1.344, P = 0.002). This is the first study to compare the frequency of AE-IP after pulmonary surgery with that after non-pulmonary surgery performed under the same conditions. The results suggest that the frequency of AE-IP after non-pulmonary surgery is similar to that after pulmonary surgery. A high preoperative C-reactive protein level is a potential risk factor for AE-IP after non-pulmonary surgery.

6 June 2017 in Surgery Today
Verified
Journal Article
Closed access
PDF file
DTDaisuke Taniguchi
Daisuke Taniguchi
NYNaoya Yamasaki
Naoya Yamasaki
TMTakuro Miyazaki
Takuro Miyazaki
Tomoshi TsuchiyaTomoshi Tsuchiya
Tomoshi Tsuchiya
KMKeitaro Matsumoto
Keitaro Matsumoto
TNTakeshi Nagayasu
Takeshi Nagayasu

12 October 2022 in Acta Biomaterialia
Verified
Journal Article
Closed access
KTKatsunori Takagi
Katsunori Takagi
KMKeitaro Matsumoto
Keitaro Matsumoto
DTDaisuke Taniguchi
Daisuke Taniguchi
RMRyusuke Machino
Ryusuke Machino
FUFumitake Uchida
Fumitake Uchida
TNTakeshi Nagayasu
Takeshi Nagayasu

28 March 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
KLKEIBUN LIU
KEIBUN LIU
Toru KotaniToru Kotani
Toru Kotani
KNKensuke Nakamura
Kensuke Nakamura
TCTakai Chihiro
Takai Chihiro
YMYasunari Morita
Yasunari Morita
TOTakayuki Ogura
Takayuki Ogura
Introduction Sepsis is not only the leading cause of death in the intensive care unit (ICU) but also a major risk factor for physical and cognitive impairment and mental disorders, known as postintensive care syndrome (PICS), reduced health-related quality of life (HRQoL) and even mental health disorders in patient families (PICS-family; PICS-F). The ABCDEF bundle is strongly recommended to overcome them, while the association between implementing the bundle and the long-term outcomes is also unknown. Methods and analysis This is a multicentre prospective observational study at 26 ICUs. All consecutive patients between 1 November 2020 and 30 April 2022, who are 18 years old or older and expected to stay in an ICU for more than 48 hours due to sepsis or septic shock, are enrolled. Follow-up to evaluate survival and PICS/ PICS-F will be performed at 3, 6 and 12 months and additionally every 6 months up to 5 years after hospital discharge. Primary outcomes include survival at 12 months, which is the primary outcome, and the incidence of PICS defined as the presence of any physical impairment, cognitive impairment or mental disorders. PICS assessment scores, HRQoL and employment status are evaluated. The association between the implementation rate for the ABCDEF bundle and for each of the individual elements and long-term outcomes will be evaluated. The PICS-F, defined as the presence of mental disorders, and HRQoL of the family is also assessed. Additional analyses with data up to 5 years follow-up are planned. Ethics and dissemination This study received ethics approvals from Saiseikai Utsunomiya Hospital (2020-42) and all other participating institutions and was registered in the University Hospital Medical Information Network Clinical Trials Registry. Informed consent will be obtained from all patients. The findings will be published in peer-reviewed journals and presented at scientific conferences. Trial registration number UMIN000041433.